Latest TCG Crossover Management, LLC Stock Portfolio
TCG Crossover Management, LLC Performance:
2025 Q3: 92.83%YTD: 72.7%2024: -19.85%
Performance for 2025 Q3 is 92.83%, and YTD is 72.7%, and 2024 is -19.85%.
About TCG Crossover Management, LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, TCG Crossover Management, LLC reported an equity portfolio of $2 Billions as of 30 Sep, 2025.
The top stock holdings of TCG Crossover Management, LLC are , , COGT. The fund has invested 29.7% of it's portfolio in ABIVAX SA AMERICAN DEPOSITARY SHARES and 7.3% of portfolio in CG ONCOLOGY INC.
The fund managers got completely rid off CIDARA THERAPEUTICS INC (CDTX), SOLENO THERAPEUTICS INC (SLNO) and THIRD HARMONIC BIO INC (THRD) stocks. They significantly reduced their stock positions in UPSTREAM BIO INC, TANGO THERAPEUTICS INC (TNGX) and ADVERUM BIOTECHNOLOGIES INC (ADVM). TCG Crossover Management, LLC opened new stock positions in LIQUIDIA TECHNOLOGIES INC (LQDA), LB PHARMACEUTICALS INC and REVOLUTION MEDICINES INC (RVMD). The fund showed a lot of confidence in some stocks as they added substantially to AGIOS PHARMACEUTICALS INC (AGIO), DYNE THERAPEUTICS INC (DYN) and ABIVAX SA AMERICAN DEPOSITARY SHARES.
The top stock holdings of TCG Crossover Management, LLC are , , COGT. The fund has invested 29.7% of it's portfolio in ABIVAX SA AMERICAN DEPOSITARY SHARES and 7.3% of portfolio in CG ONCOLOGY INC.
The fund managers got completely rid off CIDARA THERAPEUTICS INC (CDTX), SOLENO THERAPEUTICS INC (SLNO) and THIRD HARMONIC BIO INC (THRD) stocks. They significantly reduced their stock positions in UPSTREAM BIO INC, TANGO THERAPEUTICS INC (TNGX) and ADVERUM BIOTECHNOLOGIES INC (ADVM). TCG Crossover Management, LLC opened new stock positions in LIQUIDIA TECHNOLOGIES INC (LQDA), LB PHARMACEUTICALS INC and REVOLUTION MEDICINES INC (RVMD). The fund showed a lot of confidence in some stocks as they added substantially to AGIOS PHARMACEUTICALS INC (AGIO), DYNE THERAPEUTICS INC (DYN) and ABIVAX SA AMERICAN DEPOSITARY SHARES.
TCG Crossover Management, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that TCG Crossover Management, LLC made a return of 92.83% in the last quarter. In trailing 12 months, it's portfolio return was 38.35%.
New Buys
| Ticker | $ Bought |
|---|---|
| liquidia technologies inc | 38,887,300 |
| lb pharmaceuticals inc | 27,553,800 |
| revolution medicines inc | 20,383,300 |
| korro bio inc | 19,936,700 |
| spyre therapeutics inc | 18,445,800 |
| urogen pharma ltd | 14,311,100 |
| arvinas holding co llc | 13,780,000 |
| monopar therapeutics inc | 12,495,500 |
New stocks bought by TCG Crossover Management, LLC
Additions
| Ticker | % Inc. |
|---|---|
| agios pharmaceuticals inc | 105 |
| dyne therapeutics inc | 22.53 |
| abivax sa american depositary shares | 17.42 |
| ocular therapeutix inc | 15.00 |
| dianthus therapeutics inc | 11.65 |
| centessa pharmaceuticals plc | 8.5 |
| amylyx pharmaceuticals inc | 5.05 |
Additions to existing portfolio by TCG Crossover Management, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| upstream bio inc | -24.44 |
| tango therapeutics inc | -20.49 |
| tourmaline bio inc | -11.22 |
| adverum biotechnologies inc | -7.14 |
| cogent biosciences inc | -2.39 |
TCG Crossover Management, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| third harmonic bio inc | -10,400,800 |
| cidara therapeutics inc | -48,997,400 |
| kura oncology inc | -4,242,010 |
| enliven therapeutics, inc. | -9,989,880 |
| nektar therapeutics | -6,890,650 |
| soleno therapeutics inc | -15,604,000 |
| cabaletta bio inc | -131,928 |
| jade biosciences inc | -639,590 |
TCG Crossover Management, LLC got rid off the above stocks
Sector Distribution
TCG Crossover Management, LLC has about 52.4% of it's holdings in Others sector.
| Sector | % |
|---|---|
| Others | 52.4 |
| Healthcare | 47.6 |
Market Cap. Distribution
TCG Crossover Management, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 52.7 |
| SMALL-CAP | 32.1 |
| MICRO-CAP | 7.6 |
| MID-CAP | 6.7 |
Stocks belong to which Index?
About 39% of the stocks held by TCG Crossover Management, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 61 |
| RUSSELL 2000 | 39 |
TCG Crossover Management, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of TCG Crossover Management, LLC
TCG Crossover Management, LLC has 40 stocks in it's portfolio. About 65.9% of the portfolio is in top 10 stocks. proved to be the most loss making stock for the portfolio. was the most profitable stock for TCG Crossover Management, LLC last quarter.
Last Reported on: 17 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ADCT | adc therapeutics sa | 0.27 | 1,390,180 | 5,560,700 | new | |||
| ADVM | adverum biotechnologies inc | 0.37 | 1,668,170 | 7,556,830 | reduced | -7.14 | ||
| AGIO | agios pharmaceuticals inc | 2.82 | 1,430,040 | 57,401,800 | added | 105 | ||
| AGLE | spyre therapeutics inc | 0.91 | 1,100,580 | 18,445,800 | new | |||
| AMLX | amylyx pharmaceuticals inc | 4.17 | 6,243,810 | 84,853,400 | added | 5.05 | ||
| ARVN | arvinas holding co llc | 0.68 | 1,617,360 | 13,780,000 | new | |||
| ATXS | astria therapeutics inc | 0.99 | 2,761,860 | 20,106,300 | unchanged | 0.00 | ||
| AVTE | jade biosciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AVTX | avalo therapeutics inc | 0.30 | 483,000 | 6,138,930 | unchanged | 0.00 | ||
| CABA | cabaletta bio inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CDTX | cidara therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CNTA | centessa pharmaceuticals plc | 3.74 | 3,136,480 | 76,059,600 | added | 8.5 | ||
| COGT | cogent biosciences inc | 4.80 | 6,798,160 | 97,621,600 | reduced | -2.39 | ||
| DYN | dyne therapeutics inc | 2.87 | 4,615,140 | 58,381,600 | added | 22.53 | ||
| EYPT | eyepoint pharmaceuticals inc | 2.50 | 3,572,340 | 50,870,000 | unchanged | 0.00 | ||
| FULC | fulcrum therapeutics inc | 2.38 | 5,250,000 | 48,300,000 | unchanged | 0.00 | ||
| KOD | kodiak sciences inc | 0.92 | 1,145,540 | 18,752,500 | unchanged | 0.00 | ||
| KROS | keros therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | |||
| KURA | kura oncology inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| LQDA | liquidia technologies inc | 1.91 | 1,710,080 | 38,887,300 | new | |||